Gentian Diagnostics ASA

Regulatory Filings • Jan 30, 2017

Gentian Diagnostics AS Company Announcement:

Moss, 30.01.2017: Announcement 5-17

WIPO has published new Gentian patent application

An international patent application, PCT/EP2016/067639, was published on the 26th of January 2017 by the World Intellectual Property Organization, describing Gentians proprietary technology for more efficient CD4-posive lymphocyte measurements in blood.

Gentian Diagnostics is conducting a EUROSTARS funded R&D project in the area of monitoring therapy of HIV infections. Today many patients suffering from HIV infections are receiving efficient medical treatment and can expect longer lives and less complications from the infections, provided that the treatment is guided by measurements of the blood´s content of white blood cells carrying the molecules necessary for fighting the infections (so called CD4 positive lymphocytes) and the bloods content of the HIV viruses (so called "viral load» of the blood).

See link: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017013267&redirectedID=true

For further information, please contact:

Bård Sundrehagen, CEO Telephone: +47 924 14 117 E-mail: info@gentian.no

About Gentian

Gentian designs, develops and manufactures in vitro diagnostic (IVD) reagents and materials with the goal to offer more efficient and accurate test solutions in the areas of kidney disease, cardiovascular diseases, inflammation and oncology. Our customers are clinical and research laboratories worldwide who seek new and effective diagnostic solutions for their patients as well as more efficient solutions with respect to cost and workflow. Gentian exists to meet these needs.

Gentian Diagnostics AS is listed on Merkur Market at Oslo Stock Exchange with ticker GENT_ME